Mesenchymal stem cell-derived exosomal microRNA-133b suppresses glioma progression via Wnt/β-catenin signaling pathway by targeting EZH2
Mesenchymal stem cells (MSCs) play a significant role in cancer initiation and metastasis, sometimes by releasing exosomes that mediate cell communication by delivering microRNAs (miRNAs). This study aimed to investigate the effects of exosomal miR-133b derived from MSCs on glioma cell behaviors. Mi...
Saved in:
Published in | Stem cell research & therapy Vol. 10; no. 1; pp. 381 - 14 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central
16.12.2019
BMC |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Mesenchymal stem cells (MSCs) play a significant role in cancer initiation and metastasis, sometimes by releasing exosomes that mediate cell communication by delivering microRNAs (miRNAs). This study aimed to investigate the effects of exosomal miR-133b derived from MSCs on glioma cell behaviors.
Microarray-based analysis identified the differentially expressed genes (DEGs) in glioma. The expression patterns of EZH2 and miR-133b along with interaction between them were clarified in glioma. The expression of miR-133b and EZH2 in glioma cells was altered to examine their functions on cell activities. Furthermore, glioma cells were co-cultured with MSC-derived exosomes treated with miR-133b mimic or inhibitor, and EZH2-over-expressing vectors or shRNA against EZH2 to characterize their effect on proliferation, invasion, and migration of glioma cells in vitro. In vivo assays were also performed to validate the in vitro findings.
miR-133b was downregulated while EZH2 was upregulated in glioma tissues and cells. miR-133b was found to target and negatively regulate EZH2 expression. Moreover, EZH2 silencing resulted in inhibited glioma cell proliferation, invasion, and migration. Additionally, MSC-derived exosomes containing miR-133b repressed glioma cell proliferation, invasion, and migration by inhibiting EZH2 and the Wnt/β-catenin signaling pathway. Furthermore, in vivo experiments confirmed the tumor-suppressive effects of MSC-derived exosomal miR-133b on glioma development.
Collectively, the obtained results suggested that MSC-derived exosomes carrying miR-133b could attenuate glioma development via disrupting the Wnt/β-catenin signaling pathway by inhibiting EZH2, which provides a potential treatment biomarker for glioma. |
---|---|
AbstractList | Mesenchymal stem cells (MSCs) play a significant role in cancer initiation and metastasis, sometimes by releasing exosomes that mediate cell communication by delivering microRNAs (miRNAs). This study aimed to investigate the effects of exosomal miR-133b derived from MSCs on glioma cell behaviors.BACKGROUNDMesenchymal stem cells (MSCs) play a significant role in cancer initiation and metastasis, sometimes by releasing exosomes that mediate cell communication by delivering microRNAs (miRNAs). This study aimed to investigate the effects of exosomal miR-133b derived from MSCs on glioma cell behaviors.Microarray-based analysis identified the differentially expressed genes (DEGs) in glioma. The expression patterns of EZH2 and miR-133b along with interaction between them were clarified in glioma. The expression of miR-133b and EZH2 in glioma cells was altered to examine their functions on cell activities. Furthermore, glioma cells were co-cultured with MSC-derived exosomes treated with miR-133b mimic or inhibitor, and EZH2-over-expressing vectors or shRNA against EZH2 to characterize their effect on proliferation, invasion, and migration of glioma cells in vitro. In vivo assays were also performed to validate the in vitro findings.METHODSMicroarray-based analysis identified the differentially expressed genes (DEGs) in glioma. The expression patterns of EZH2 and miR-133b along with interaction between them were clarified in glioma. The expression of miR-133b and EZH2 in glioma cells was altered to examine their functions on cell activities. Furthermore, glioma cells were co-cultured with MSC-derived exosomes treated with miR-133b mimic or inhibitor, and EZH2-over-expressing vectors or shRNA against EZH2 to characterize their effect on proliferation, invasion, and migration of glioma cells in vitro. In vivo assays were also performed to validate the in vitro findings.miR-133b was downregulated while EZH2 was upregulated in glioma tissues and cells. miR-133b was found to target and negatively regulate EZH2 expression. Moreover, EZH2 silencing resulted in inhibited glioma cell proliferation, invasion, and migration. Additionally, MSC-derived exosomes containing miR-133b repressed glioma cell proliferation, invasion, and migration by inhibiting EZH2 and the Wnt/β-catenin signaling pathway. Furthermore, in vivo experiments confirmed the tumor-suppressive effects of MSC-derived exosomal miR-133b on glioma development.RESULTSmiR-133b was downregulated while EZH2 was upregulated in glioma tissues and cells. miR-133b was found to target and negatively regulate EZH2 expression. Moreover, EZH2 silencing resulted in inhibited glioma cell proliferation, invasion, and migration. Additionally, MSC-derived exosomes containing miR-133b repressed glioma cell proliferation, invasion, and migration by inhibiting EZH2 and the Wnt/β-catenin signaling pathway. Furthermore, in vivo experiments confirmed the tumor-suppressive effects of MSC-derived exosomal miR-133b on glioma development.Collectively, the obtained results suggested that MSC-derived exosomes carrying miR-133b could attenuate glioma development via disrupting the Wnt/β-catenin signaling pathway by inhibiting EZH2, which provides a potential treatment biomarker for glioma.CONCLUSIONCollectively, the obtained results suggested that MSC-derived exosomes carrying miR-133b could attenuate glioma development via disrupting the Wnt/β-catenin signaling pathway by inhibiting EZH2, which provides a potential treatment biomarker for glioma. Abstract Background Mesenchymal stem cells (MSCs) play a significant role in cancer initiation and metastasis, sometimes by releasing exosomes that mediate cell communication by delivering microRNAs (miRNAs). This study aimed to investigate the effects of exosomal miR-133b derived from MSCs on glioma cell behaviors. Methods Microarray-based analysis identified the differentially expressed genes (DEGs) in glioma. The expression patterns of EZH2 and miR-133b along with interaction between them were clarified in glioma. The expression of miR-133b and EZH2 in glioma cells was altered to examine their functions on cell activities. Furthermore, glioma cells were co-cultured with MSC-derived exosomes treated with miR-133b mimic or inhibitor, and EZH2-over-expressing vectors or shRNA against EZH2 to characterize their effect on proliferation, invasion, and migration of glioma cells in vitro. In vivo assays were also performed to validate the in vitro findings. Results miR-133b was downregulated while EZH2 was upregulated in glioma tissues and cells. miR-133b was found to target and negatively regulate EZH2 expression. Moreover, EZH2 silencing resulted in inhibited glioma cell proliferation, invasion, and migration. Additionally, MSC-derived exosomes containing miR-133b repressed glioma cell proliferation, invasion, and migration by inhibiting EZH2 and the Wnt/β-catenin signaling pathway. Furthermore, in vivo experiments confirmed the tumor-suppressive effects of MSC-derived exosomal miR-133b on glioma development. Conclusion Collectively, the obtained results suggested that MSC-derived exosomes carrying miR-133b could attenuate glioma development via disrupting the Wnt/β-catenin signaling pathway by inhibiting EZH2, which provides a potential treatment biomarker for glioma. Background Mesenchymal stem cells (MSCs) play a significant role in cancer initiation and metastasis, sometimes by releasing exosomes that mediate cell communication by delivering microRNAs (miRNAs). This study aimed to investigate the effects of exosomal miR-133b derived from MSCs on glioma cell behaviors. Methods Microarray-based analysis identified the differentially expressed genes (DEGs) in glioma. The expression patterns of EZH2 and miR-133b along with interaction between them were clarified in glioma. The expression of miR-133b and EZH2 in glioma cells was altered to examine their functions on cell activities. Furthermore, glioma cells were co-cultured with MSC-derived exosomes treated with miR-133b mimic or inhibitor, and EZH2-over-expressing vectors or shRNA against EZH2 to characterize their effect on proliferation, invasion, and migration of glioma cells in vitro. In vivo assays were also performed to validate the in vitro findings. Results miR-133b was downregulated while EZH2 was upregulated in glioma tissues and cells. miR-133b was found to target and negatively regulate EZH2 expression. Moreover, EZH2 silencing resulted in inhibited glioma cell proliferation, invasion, and migration. Additionally, MSC-derived exosomes containing miR-133b repressed glioma cell proliferation, invasion, and migration by inhibiting EZH2 and the Wnt/β-catenin signaling pathway. Furthermore, in vivo experiments confirmed the tumor-suppressive effects of MSC-derived exosomal miR-133b on glioma development. Conclusion Collectively, the obtained results suggested that MSC-derived exosomes carrying miR-133b could attenuate glioma development via disrupting the Wnt/β-catenin signaling pathway by inhibiting EZH2, which provides a potential treatment biomarker for glioma. Mesenchymal stem cells (MSCs) play a significant role in cancer initiation and metastasis, sometimes by releasing exosomes that mediate cell communication by delivering microRNAs (miRNAs). This study aimed to investigate the effects of exosomal miR-133b derived from MSCs on glioma cell behaviors. Microarray-based analysis identified the differentially expressed genes (DEGs) in glioma. The expression patterns of EZH2 and miR-133b along with interaction between them were clarified in glioma. The expression of miR-133b and EZH2 in glioma cells was altered to examine their functions on cell activities. Furthermore, glioma cells were co-cultured with MSC-derived exosomes treated with miR-133b mimic or inhibitor, and EZH2-over-expressing vectors or shRNA against EZH2 to characterize their effect on proliferation, invasion, and migration of glioma cells in vitro. In vivo assays were also performed to validate the in vitro findings. miR-133b was downregulated while EZH2 was upregulated in glioma tissues and cells. miR-133b was found to target and negatively regulate EZH2 expression. Moreover, EZH2 silencing resulted in inhibited glioma cell proliferation, invasion, and migration. Additionally, MSC-derived exosomes containing miR-133b repressed glioma cell proliferation, invasion, and migration by inhibiting EZH2 and the Wnt/β-catenin signaling pathway. Furthermore, in vivo experiments confirmed the tumor-suppressive effects of MSC-derived exosomal miR-133b on glioma development. Collectively, the obtained results suggested that MSC-derived exosomes carrying miR-133b could attenuate glioma development via disrupting the Wnt/β-catenin signaling pathway by inhibiting EZH2, which provides a potential treatment biomarker for glioma. |
ArticleNumber | 381 |
Author | Yu, Hongquan Zhao, Guifang Hong, Jin Zhang, Yu Zhao, Donghai Jiang, Hong Qi, Ling Wang, Weiyao Xu, Haiyang |
Author_xml | – sequence: 1 givenname: Haiyang surname: Xu fullname: Xu, Haiyang – sequence: 2 givenname: Guifang surname: Zhao fullname: Zhao, Guifang – sequence: 3 givenname: Yu surname: Zhang fullname: Zhang, Yu – sequence: 4 givenname: Hong surname: Jiang fullname: Jiang, Hong – sequence: 5 givenname: Weiyao surname: Wang fullname: Wang, Weiyao – sequence: 6 givenname: Donghai surname: Zhao fullname: Zhao, Donghai – sequence: 7 givenname: Jin surname: Hong fullname: Hong, Jin – sequence: 8 givenname: Hongquan surname: Yu fullname: Yu, Hongquan – sequence: 9 givenname: Ling surname: Qi fullname: Qi, Ling |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31842978$$D View this record in MEDLINE/PubMed |
BookMark | eNp9ks1u1DAUhSNUREvpA7BBltiwCfVP4iQbpKoqtFIBCYGQ2Fg39k3GoyQebM_A9A14HR6EZ8LplKrtAm9sXX_36NrnPM32Jjdhlj1n9DVjtTwOTPC6yilrclYUMr96lB2wqqxyWTK-d-e8nx2FsKRpCUGpLJ5k-4LVBW-q-iD79R4DTnqxHWEgIeJINA5DbtDbDRqCP11w89VotXefPpzkTIiWhPVq5TEEDKQfbALIyrt-rlg3kY0F8nWKx39-5xoiTnYiwfYTDHbqyQri4gdsSbslEXyPcS6efTvnz7LHHQwBj272w-zL27PPp-f55cd3F6cnl7kuGhHzjnamwpIixwqgMgitMC1yU9YMKXRCFgwo00Z2HS2FbFtqBMgaS46Mt1ocZhc7XeNgqVbejuC3yoFV1wXnewU-Wj2gklx3stYAsuSFZtAyJivDa1GjoabEpPVmp7VatyMajVP0MNwTvX8z2YXq3UbJhpUNK5LAqxsB776vMUQ12jA7ABO6dVBc8KopuKxEQl8-QJdu7dOvXlN1WXIqWaJe3J3odpR_jieA7YDkZwgeu1uEUTUHS-2CpVKw1BwsdZV6qgc92kaIyev0KDv8p_MvlurWNg |
CitedBy_id | crossref_primary_10_3390_pharmaceutics14051054 crossref_primary_10_1007_s10620_020_06458_1 crossref_primary_10_1111_jcmm_17933 crossref_primary_10_18632_oncotarget_27622 crossref_primary_10_3389_fcell_2024_1459246 crossref_primary_10_1016_j_biopha_2023_115505 crossref_primary_10_1155_2020_8844730 crossref_primary_10_3389_fcell_2020_574940 crossref_primary_10_3389_fonc_2021_733529 crossref_primary_10_1039_D4BM01394H crossref_primary_10_3390_ijms23020625 crossref_primary_10_1016_j_ncrna_2024_11_004 crossref_primary_10_3389_fcell_2021_740783 crossref_primary_10_1186_s12935_022_02642_7 crossref_primary_10_1186_s12964_020_00623_9 crossref_primary_10_3389_fphar_2024_1438177 crossref_primary_10_1093_hmg_ddac130 crossref_primary_10_3390_pharmaceutics15051439 crossref_primary_10_1002_jcp_30495 crossref_primary_10_3389_fonc_2023_1299384 crossref_primary_10_1002_wrna_1735 crossref_primary_10_2147_JIR_S429532 crossref_primary_10_3389_fbioe_2021_652970 crossref_primary_10_3390_bioengineering10010051 crossref_primary_10_3390_biom14111354 crossref_primary_10_1007_s12032_025_02648_x crossref_primary_10_1111_jcmm_16970 crossref_primary_10_1007_s10565_022_09759_5 crossref_primary_10_1016_j_apsb_2022_11_019 crossref_primary_10_3390_ijms22073576 crossref_primary_10_3390_cells13070617 crossref_primary_10_1016_j_mtbio_2025_101646 crossref_primary_10_3389_fnmol_2022_1004221 crossref_primary_10_3389_fonc_2022_1047907 crossref_primary_10_1021_acsbiomaterials_3c00212 crossref_primary_10_1016_j_ijbiomac_2023_128722 crossref_primary_10_1007_s10495_021_01674_0 crossref_primary_10_3389_fimmu_2021_813747 crossref_primary_10_1016_j_cellsig_2022_110493 crossref_primary_10_3390_cancers13051157 crossref_primary_10_1093_jpp_rgae086 crossref_primary_10_3390_ijms241210162 crossref_primary_10_1016_j_yexcr_2020_112321 crossref_primary_10_1016_j_ijbiomac_2024_130728 crossref_primary_10_1007_s12015_020_10082_x crossref_primary_10_3390_cancers12092486 crossref_primary_10_3390_biom14121519 crossref_primary_10_3390_ph17060707 crossref_primary_10_1002_jnr_25134 crossref_primary_10_3390_cancers15245847 crossref_primary_10_1007_s13577_022_00753_x crossref_primary_10_1016_j_biopha_2021_112532 crossref_primary_10_1080_10799893_2021_1918166 crossref_primary_10_1016_j_jconrel_2021_12_024 crossref_primary_10_34133_research_0421 crossref_primary_10_1080_10717544_2022_2104404 crossref_primary_10_3390_ijms23052745 crossref_primary_10_1016_j_lfs_2024_123150 crossref_primary_10_1016_j_neubiorev_2023_105206 crossref_primary_10_1007_s13205_021_02922_5 crossref_primary_10_1016_j_critrevonc_2021_103547 crossref_primary_10_3389_fimmu_2023_1175118 crossref_primary_10_3892_etm_2021_10950 crossref_primary_10_3389_fcvm_2021_737512 crossref_primary_10_1007_s11010_021_04053_0 crossref_primary_10_1186_s12935_024_03507_x crossref_primary_10_1002_mco2_49 crossref_primary_10_1007_s10565_021_09652_7 crossref_primary_10_3892_ijo_2024_5712 crossref_primary_10_1155_2021_4907167 crossref_primary_10_3389_fbioe_2022_1019459 crossref_primary_10_1002_sctm_20_0161 crossref_primary_10_18097_pbmc20226806419 crossref_primary_10_1016_j_lfs_2022_121103 crossref_primary_10_1038_s41392_022_01298_z crossref_primary_10_18632_aging_202923 crossref_primary_10_1002_adma_202005709 crossref_primary_10_1038_s41417_022_00427_8 crossref_primary_10_15252_embj_2021109288 crossref_primary_10_1155_2022_8071343 crossref_primary_10_2147_IJN_S407029 crossref_primary_10_1007_s12094_022_02966_w crossref_primary_10_1016_j_yexcr_2022_113208 crossref_primary_10_1016_j_vesic_2024_100049 crossref_primary_10_1016_j_bbcan_2022_188700 crossref_primary_10_1007_s10616_024_00631_4 crossref_primary_10_1016_j_bioactmat_2021_05_038 crossref_primary_10_3390_ijms222011187 crossref_primary_10_1038_s41392_022_01134_4 crossref_primary_10_1111_cpr_12833 crossref_primary_10_1186_s10020_024_00857_0 crossref_primary_10_3389_fbioe_2022_956563 crossref_primary_10_1186_s13287_020_01676_w crossref_primary_10_1186_s13287_022_03212_4 crossref_primary_10_1080_02648725_2023_2204720 crossref_primary_10_1016_j_ajps_2021_08_003 crossref_primary_10_1016_j_biopha_2022_113554 crossref_primary_10_1186_s12935_021_02144_y crossref_primary_10_1155_2021_5589342 crossref_primary_10_1007_s13346_024_01710_x crossref_primary_10_1515_oncologie_2023_0482 crossref_primary_10_3390_biomedicines12081822 crossref_primary_10_18632_aging_204513 crossref_primary_10_1016_j_biopha_2021_112187 crossref_primary_10_3390_pharmaceutics13070988 crossref_primary_10_1186_s13287_023_03551_w crossref_primary_10_1016_j_canlet_2023_216592 crossref_primary_10_3390_ijms23031353 crossref_primary_10_3390_cimb45040208 crossref_primary_10_1186_s13578_021_00620_6 crossref_primary_10_3389_fcell_2023_1255697 crossref_primary_10_18632_aging_202747 crossref_primary_10_1038_s41598_024_68922_6 crossref_primary_10_1016_j_biopha_2023_115405 crossref_primary_10_3390_cells12091247 crossref_primary_10_3390_pharmaceutics14010116 crossref_primary_10_1016_j_jconrel_2023_04_038 crossref_primary_10_3390_ijms222212204 crossref_primary_10_3390_ijms231810972 crossref_primary_10_1007_s11033_021_06687_1 crossref_primary_10_1002_2211_5463_13352 |
Cites_doi | 10.1016/j.biopha.2016.11.053 10.3892/ol.2015.3657 10.1016/j.neuint.2014.06.002 10.1517/14712598.2012.680018 10.18632/oncotarget.9198 10.7717/peerj.4336 10.1186/s13046-017-0567-4 10.1111/j.1365-2990.2010.01132.x 10.18632/oncotarget.10370 10.1371/journal.pone.0092129 10.5483/BMBRep.2018.51.8.105 10.1002/stem.1247 10.1371/journal.pone.0169932 10.3109/07357907.2012.692171 10.1111/jth.12602 10.3390/ijms18020372 10.7717/peerj.4196 10.18632/oncotarget.21311 10.1093/neuonc/nou087 10.18632/oncotarget.9236 10.1006/meth.2001.1262 10.1371/journal.pone.0181346 10.3390/genes9020105 10.1016/j.jns.2013.09.030 10.2741/3952 10.1158/0008-5472.CAN-16-2524 10.12954/PI.12011 10.1593/tlo.13640 10.1007/s10555-010-9222-7 10.18632/oncotarget.868 10.2741/4362 10.1016/j.canlet.2011.10.002 10.18632/oncotarget.424 |
ContentType | Journal Article |
Copyright | 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s). 2019 |
Copyright_xml | – notice: 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s). 2019 |
DBID | AAYXX CITATION NPM 3V. 7X7 7XB 88E 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 5PM DOA |
DOI | 10.1186/s13287-019-1446-z |
DatabaseName | CrossRef PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection Medical Database Biological Science Database ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database PubMed |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 1757-6512 |
EndPage | 14 |
ExternalDocumentID | oai_doaj_org_article_62cf68caa6524c1ab1167d2838ed0d5e PMC6915914 31842978 10_1186_s13287_019_1446_z |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GeographicLocations | United States--US China Japan |
GeographicLocations_xml | – name: China – name: United States--US – name: Japan |
GrantInformation_xml | – fundername: ; grantid: 81201671 – fundername: ; grantid: 201920190201090JC, 20190101006JH, 20180101306JC |
GroupedDBID | --- 0R~ 53G 5VS 7X7 88E 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AASML AAYXX ABDBF ABUWG ACGFS ACIHN ACJQM ACPRK ACUHS ADBBV ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIAM AOIJS BAPOH BAWUL BBNVY BCNDV BENPR BFQNJ BHPHI BMC BPHCQ BVXVI C6C CCPQU CITATION DIK E3Z EBD EBLON EBS EJD EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HCIFZ HMCUK HYE IAO IEA IHR IHW INH INR ISR ITC KQ8 LK8 M1P M7P M~E O5R O5S OK1 P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ ROL RPM RSV SBL SOJ SV3 TUS UKHRP -56 -5G -BR 3V. ACRMQ ADINQ C24 NPM 7XB 8FK AZQEC DWQXO GNUQQ K9. PJZUB PKEHL PPXIY PQEST PQGLB PQUKI PRINS 7X8 5PM PUEGO |
ID | FETCH-LOGICAL-c493t-f0fd7e50e2e7aa7deab3dbe2d581e0af3641a01cd6ff0536bb0d3a68e52e12bc3 |
IEDL.DBID | DOA |
ISSN | 1757-6512 |
IngestDate | Wed Aug 27 01:27:42 EDT 2025 Thu Aug 21 18:15:29 EDT 2025 Fri Jul 11 06:59:49 EDT 2025 Fri Jul 25 09:41:49 EDT 2025 Thu Jan 02 22:58:55 EST 2025 Tue Jul 01 00:43:23 EDT 2025 Thu Apr 24 22:53:38 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Glioma Wnt/β-catenin signaling pathway Exosomes MicroRNA-133b EZH2 Mesenchymal stem cells |
Language | English |
License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c493t-f0fd7e50e2e7aa7deab3dbe2d581e0af3641a01cd6ff0536bb0d3a68e52e12bc3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
OpenAccessLink | https://doaj.org/article/62cf68caa6524c1ab1167d2838ed0d5e |
PMID | 31842978 |
PQID | 2328552061 |
PQPubID | 2040189 |
PageCount | 14 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_62cf68caa6524c1ab1167d2838ed0d5e pubmedcentral_primary_oai_pubmedcentral_nih_gov_6915914 proquest_miscellaneous_2327942673 proquest_journals_2328552061 pubmed_primary_31842978 crossref_primary_10_1186_s13287_019_1446_z crossref_citationtrail_10_1186_s13287_019_1446_z |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2019-12-16 |
PublicationDateYYYYMMDD | 2019-12-16 |
PublicationDate_xml | – month: 12 year: 2019 text: 2019-12-16 day: 16 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | Stem cell research & therapy |
PublicationTitleAlternate | Stem Cell Res Ther |
PublicationYear | 2019 |
Publisher | BioMed Central BMC |
Publisher_xml | – name: BioMed Central – name: BMC |
References | IA Ho (1446_CR7) 2013; 31 WT Kim (1446_CR12) 2013; 1 Z Wu (1446_CR32) 2013; 335 R Domenis (1446_CR30) 2017; 12 JJ Zhang (1446_CR35) 2017; 85 T Yu (1446_CR28) 2017; 8 Mariachiara Zuccarini (1446_CR21) 2018; 9 C Li (1446_CR16) 2016; 7 Q Li (1446_CR3) 2015; 8 N Nohata (1446_CR14) 2012; 3 X Jiang (1446_CR33) 2017; 5 J Sun (1446_CR26) 2017; 36 W Xiong (1446_CR1) 2018; 39 HK Lee (1446_CR34) 2013; 4 Y Wang (1446_CR19) 2016; 7 J Figueroa (1446_CR10) 2017; 77 W Zhu (1446_CR8) 2012; 315 QT Ostrom (1446_CR2) 2014; 16 KJ Livak (1446_CR22) 2001; 25 F Orzan (1446_CR17) 2011; 37 MY Li (1446_CR29) 2017; 33 T Zeng (1446_CR4) 2015; 20 H Ye (1446_CR6) 2012; 30 Cecilia Lässer (1446_CR11) 2012; 12 E van der Pol (1446_CR25) 2014; 12 SA Bergfeld (1446_CR5) 2010; 29 X Fu (1446_CR23) 2018; 6 G Zhang (1446_CR24) 2014; 9 WT Arscott (1446_CR9) 2013; 6 JF Chen (1446_CR36) 2016; 7 L Gao (1446_CR20) 2017; 12 L Chang (1446_CR15) 2015; 10 Ssu-Yin Yen (1446_CR18) 2017; 18 Y Zhang (1446_CR13) 2012; 17 R Kim (1446_CR27) 2018; 51 1446_CR31 |
References_xml | – volume: 8 start-page: 12234 issue: 10 year: 2015 ident: 1446_CR3 publication-title: Int J Clin Exp Pathol – volume: 85 start-page: 472 year: 2017 ident: 1446_CR35 publication-title: Biomed Pharmacother doi: 10.1016/j.biopha.2016.11.053 – volume: 10 start-page: 2781 issue: 5 year: 2015 ident: 1446_CR15 publication-title: Oncol Lett doi: 10.3892/ol.2015.3657 – ident: 1446_CR31 doi: 10.1016/j.neuint.2014.06.002 – volume: 12 start-page: S189 issue: sup1 year: 2012 ident: 1446_CR11 publication-title: Expert Opinion on Biological Therapy doi: 10.1517/14712598.2012.680018 – volume: 7 start-page: 36247 issue: 24 year: 2016 ident: 1446_CR16 publication-title: Oncotarget. doi: 10.18632/oncotarget.9198 – volume: 6 start-page: e4336 year: 2018 ident: 1446_CR23 publication-title: PeerJ doi: 10.7717/peerj.4336 – volume: 36 start-page: 100 issue: 1 year: 2017 ident: 1446_CR26 publication-title: J Exp Clin Cancer Res doi: 10.1186/s13046-017-0567-4 – volume: 37 start-page: 381 issue: 4 year: 2011 ident: 1446_CR17 publication-title: Neuropathol Appl Neurobiol doi: 10.1111/j.1365-2990.2010.01132.x – volume: 7 start-page: 49450 issue: 31 year: 2016 ident: 1446_CR19 publication-title: Oncotarget. doi: 10.18632/oncotarget.10370 – volume: 9 start-page: e92129 issue: 3 year: 2014 ident: 1446_CR24 publication-title: PLoS One doi: 10.1371/journal.pone.0092129 – volume: 51 start-page: 406 issue: 8 year: 2018 ident: 1446_CR27 publication-title: BMB Rep doi: 10.5483/BMBRep.2018.51.8.105 – volume: 31 start-page: 146 issue: 1 year: 2013 ident: 1446_CR7 publication-title: Stem Cells doi: 10.1002/stem.1247 – volume: 39 start-page: 1939 issue: 4 year: 2018 ident: 1446_CR1 publication-title: Oncol Rep – volume: 12 start-page: e0169932 issue: 1 year: 2017 ident: 1446_CR30 publication-title: PLoS One doi: 10.1371/journal.pone.0169932 – volume: 30 start-page: 513 issue: 7 year: 2012 ident: 1446_CR6 publication-title: Cancer Investig doi: 10.3109/07357907.2012.692171 – volume: 12 start-page: 1182 issue: 7 year: 2014 ident: 1446_CR25 publication-title: J Thromb Haemost doi: 10.1111/jth.12602 – volume: 18 start-page: 372 issue: 2 year: 2017 ident: 1446_CR18 publication-title: International Journal of Molecular Sciences doi: 10.3390/ijms18020372 – volume: 5 start-page: e4196 year: 2017 ident: 1446_CR33 publication-title: PeerJ doi: 10.7717/peerj.4196 – volume: 8 start-page: 98348 issue: 58 year: 2017 ident: 1446_CR28 publication-title: Oncotarget. doi: 10.18632/oncotarget.21311 – volume: 16 start-page: 896 issue: 7 year: 2014 ident: 1446_CR2 publication-title: Neuro-Oncology doi: 10.1093/neuonc/nou087 – volume: 7 start-page: 41540 issue: 27 year: 2016 ident: 1446_CR36 publication-title: Oncotarget. doi: 10.18632/oncotarget.9236 – volume: 25 start-page: 402 issue: 4 year: 2001 ident: 1446_CR22 publication-title: Methods. doi: 10.1006/meth.2001.1262 – volume: 12 start-page: e0181346 issue: 8 year: 2017 ident: 1446_CR20 publication-title: PLoS One doi: 10.1371/journal.pone.0181346 – volume: 9 start-page: 105 issue: 2 year: 2018 ident: 1446_CR21 publication-title: Genes doi: 10.3390/genes9020105 – volume: 335 start-page: 191 issue: 1–2 year: 2013 ident: 1446_CR32 publication-title: J Neurol Sci doi: 10.1016/j.jns.2013.09.030 – volume: 17 start-page: 700 year: 2012 ident: 1446_CR13 publication-title: Front Biosci doi: 10.2741/3952 – volume: 77 start-page: 5808 issue: 21 year: 2017 ident: 1446_CR10 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-16-2524 – volume: 1 start-page: 3 issue: 1 year: 2013 ident: 1446_CR12 publication-title: Prostate Int doi: 10.12954/PI.12011 – volume: 6 start-page: 638 issue: 6 year: 2013 ident: 1446_CR9 publication-title: Transl Oncol doi: 10.1593/tlo.13640 – volume: 29 start-page: 249 issue: 2 year: 2010 ident: 1446_CR5 publication-title: Cancer Metastasis Rev doi: 10.1007/s10555-010-9222-7 – volume: 4 start-page: 346 issue: 2 year: 2013 ident: 1446_CR34 publication-title: Oncotarget. doi: 10.18632/oncotarget.868 – volume: 20 start-page: 1104 year: 2015 ident: 1446_CR4 publication-title: Front Biosci doi: 10.2741/4362 – volume: 315 start-page: 28 issue: 1 year: 2012 ident: 1446_CR8 publication-title: Cancer Lett doi: 10.1016/j.canlet.2011.10.002 – volume: 33 start-page: 180 issue: 3 year: 2017 ident: 1446_CR29 publication-title: Zhonghua Shao Shang Za Zhi – volume: 3 start-page: 9 issue: 1 year: 2012 ident: 1446_CR14 publication-title: Oncotarget. doi: 10.18632/oncotarget.424 |
SSID | ssj0000330064 |
Score | 2.5358162 |
Snippet | Mesenchymal stem cells (MSCs) play a significant role in cancer initiation and metastasis, sometimes by releasing exosomes that mediate cell communication by... Background Mesenchymal stem cells (MSCs) play a significant role in cancer initiation and metastasis, sometimes by releasing exosomes that mediate cell... Abstract Background Mesenchymal stem cells (MSCs) play a significant role in cancer initiation and metastasis, sometimes by releasing exosomes that mediate... |
SourceID | doaj pubmedcentral proquest pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 381 |
SubjectTerms | Bone marrow Cell interactions Cell migration Cell proliferation Exosomes EZH2 Fluorides Glioma Glioma cells Immunoglobulins Laboratory animals Medical prognosis Mesenchymal stem cells Mesenchyme Metastases MicroRNA-133b MicroRNAs miRNA Nervous system Penicillin Plasmids Proteins Radiation therapy Signal transduction Stem cells Therapeutic applications Tumors Wnt protein Wnt/β-catenin signaling pathway β-Catenin |
SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NbtQwELagCIkL4r-BgozECcla23Gc5IQKarVCogdExYpL5J9xu1KbLM1uYfsGvA4PwjPhSbKBRahXeyJZmf_x5xlCXqW5Dc6kkmlfWqZ8zFOi3AQmM-BBcG7zHiB7pKfH6v0smw0Ft3aAVW5sYmeofeOwRj6Jnr_IMhndz5vFV4ZTo_B2dRihcZPcwtZlCOnKZ_lYY-ExWY8ud7jMFIWetDH5KhBrWTJMhNjVljvquvb_L9T8FzH5lws6vEfuDrEj3e-ZfZ_cgPoBud1Pk1w_JD8-4Esid7o-j0TYn5liVZ75KGOX4Cl8b9oGt84Rg_fxaJ_FxNHSdrXosLDQ0pOzeSSgHWSrb9dBL-eGfq6Xk18_GUKn6nlNEfFh8BE7xWnG38ya2jXtAeW4ePBlKh-R48ODT--mbJi0wJwq0yULPPgcMg4ScmNyD8am3oL0WSGAm5BqJQwXzusQotZqa7lPjS4gkyCkdeljslM3NewSyqHMHAgAF0Bxp6xyRdBWKRkgpMImhG9-eOWGNuQ4DeOs6tKRQlc9j6rIowp5VF0l5PX4yaLvwXEd8Vvk4kiI7bO7hebipBq0sdLSBV04Y3QmlRPG4m2Uj5FWAZ77DBKyt5GBatDptvojgQl5OW5HbURmmhqaVUcTDZzUeZqQJ73IjCeJ1jM6_7xISL4lTFtH3d6p56ddx29dxqhTqKfXH-sZuSM7yZZM6D2ys7xYwfMYMi3ti04vfgOcbxpq priority: 102 providerName: ProQuest |
Title | Mesenchymal stem cell-derived exosomal microRNA-133b suppresses glioma progression via Wnt/β-catenin signaling pathway by targeting EZH2 |
URI | https://www.ncbi.nlm.nih.gov/pubmed/31842978 https://www.proquest.com/docview/2328552061 https://www.proquest.com/docview/2327942673 https://pubmed.ncbi.nlm.nih.gov/PMC6915914 https://doaj.org/article/62cf68caa6524c1ab1167d2838ed0d5e |
Volume | 10 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbhMxELagCIkL4r8LJTISJyQrttfr3RwblCpCIkIRFVEvK_-MaaR2U7FJIX0DXqcP0mdivLuNEoTgwmUP9qzk9Xz2zKw_zxDyNs1tcCaVTPuBZcpjnIK4CUxmwIPg3OYtQXaix8fqwyybbZX6ipywNj1wO3F9LV3QhTNGZ1I5YWw8OPBoFAvw3GcQd1-0eVvBVLMHY5iOxrY7xhSF7tcYdhWRZTlgMQRiVzuGqMnX_ycn83eu5JbxOXpEHnZeIz1sR_uY3IHqCbnf1pFcPyU_P8Y7RO50fY5CMTMzjf_jmUd0XYKn8GNRL2LXeWTfTSeHDENGS-vVRcOChZp-PZujAG3IWm2iDno5N_RLtezfXLNImqrmFY1cDxOvr9NYx_i7WVO7pi2VPDaOTsbyGTk-Gn1-P2ZdjQXm1CBdssCDzyHjICE3JvdgbOotSJ8VArgJqVbCcOG8DgHXq7aW-9ToAjIJQlqXPid71aKCfUI5DDIHAsAFUNwpq1wRtFVKBgipsAnhtxNeui4BeayDcVY2gUihy1ZHJeqojDoqrxLybvPKRZt942_Cw6jFjWBMnN00IJzKDk7lv-CUkINbDJTdaq5L9DqLLJPo-iTkzaYb12FUpqlgsWpkcGuTOk8T8qKFzGYkuG-i2c-LhOQ7YNoZ6m5PNT9tcn3rAfqbQr38H9_2ijyQDf4lE_qA7C2_reA1ulRL2yN381neI_eGo8mnaa9ZS_icDk9-ASYEJvE |
linkProvider | Directory of Open Access Journals |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtQwELbKVgguiH8CBYwEFySrju042QNCLWy1pe0KVa2ouAT_jNuV2mRpdlu2b8DLcOBBeCbsJLuwCPXWazyJrMzn-bE_zyD0kqfaGcUZkbaribA-T_G4cYQlQF1MqU4bguxA9vfFh4PkYAn9mN2FCbTKmU2sDbUtTdgjX_WeP0sS5t3P29FXErpGhdPVWQuNBhZbMD33KVv1ZvO91-8rxjZ6e-_6pO0qQIzo8jFx1NkUEgoMUqVSC0pzq4HZJIuBKseliBWNjZXOeYRKranlSmaQMIiZNtx_9xpaFtynMh20vN4bfNyd7-pQzoOTb49P40yuVj7dywK7s0tC6kUuFhxg3Sfgf8HtvxzNv5zexm10q41W8VoDrztoCYq76HrTv3J6D33fCXeXzNH0xAuFitA4nAMQ61F9BhbDt7Iqw9BJYP3tDtaIT1U1riajmn0LFT48HnoBXJPEmgIh-Gyo8KdivPrrJwlkrWJY4MAxUeHaPA79k8_VFOspbijs4WHvc5_dR_tXooUHqFOUBTxCmEI3MRADGAeCGqGFyZzUQjAHjsc6QnT2w3PTFj4P_TeO8zoBymTe6Cj3OsqDjvKLCL2evzJqqn5cJrwetDgXDAW76wfl6WHerv9cMuNkZpSSCRMmVjqcf1kf22VgqU0gQiszDOStFanyP5iP0Iv5sF__QZmqgHJSy3iTymTKI_Swgcx8Jt5e-3AjzSKULoBpYaqLI8XwqK4xLrs-zo3F48un9Rzd6O_tbOfbm4OtJ-gmq1HOSCxXUGd8OoGnPmAb62ftKsHoy1UvzN-UBVsv |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Mesenchymal+stem+cell-derived+exosomal+microRNA-133b+suppresses+glioma+progression+via+Wnt%2F%CE%B2-catenin+signaling+pathway+by+targeting+EZH2&rft.jtitle=Stem+cell+research+%26+therapy&rft.au=Xu%2C+Haiyang&rft.au=Zhao%2C+Guifang&rft.au=Zhang%2C+Yu&rft.au=Jiang%2C+Hong&rft.date=2019-12-16&rft.issn=1757-6512&rft.eissn=1757-6512&rft.volume=10&rft.issue=1&rft_id=info:doi/10.1186%2Fs13287-019-1446-z&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s13287_019_1446_z |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1757-6512&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1757-6512&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1757-6512&client=summon |